Nearly three-quarters of patients responded to treatment.
Survival rates were similar whether maintenance was given every 12 weeks or every 4 weeks.
Gemtuzumab ozogamicin improved event-free survival and disease-free survival.
The signature was prognostic for locoregional recurrence.
Rates of SARS-CoV-2 infection and COVID-19-related death were similar among patients receiving cytotoxic and non-cytotoxic therapy.
Endocrine therapy was associated with fewer adverse events.
Younger patients had a significant decrease in sleep time on days they received dexamethasone.
Black patients were more likely than White patients to have distant metastases.
The median PFS was 8.5 months in the pasireotide arm, 12.5 months in the everolimus arm, and 16.5 months in the combination arm.
The cumulative incidence of bone fractures was below 5% in BPA recipients.
Pembrolizumab improved progression-free survival but not overall survival.
The median duration of response was 35.7 weeks with iberdomide, bortezomib, and dexamethasone compared with not reached in patients who received iberdomide, daratumumab, and dexamethasone or iberdomide, bortezomib, and carfilzomib
In patients who had received at least 2 prior therapy lines, the overall response rates were 49.9% in SCHOLAR-5 vs 94.2% in ZUMA-5.
The overall response rate was 44.7% after a median follow-up of 15 months.
The median progression-free survival was not reached in the D-Rd group compared with 34.4 months in the Rd group.